Literature DB >> 27605628

Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.

Raehannah J Jamshidi1, Laura C Sullivan1, Blaine A Jacobs1, Teresa A Chavera1, Kelly A Berg2, William P Clarke1.   

Abstract

A single administration of the κ opioid receptor (KOR) antagonist, norbinaltorphimine (norBNI), produces long-term reduction in KOR function in heterologous expression systems and brain that is mediated by activation of c-Jun N-terminal kinase (JNK). In this study, we examined the long-term effects of norBNI on adult rat peripheral sensory neurons in vivo and ex vivo. Following a single intraplantar (i.pl.) injection of norBNI into the hind paw, peripheral KOR-mediated antinociception in the ipsilateral, but not the contralateral, hindpaw was abolished for at least 9 days. By contrast, the antinociceptive response to mu and delta opioid receptor agonists was unaltered. The long-term inhibitory effect on antinociception produced by pretreatment with norBNI required occupancy of peripheral KOR and was completely blocked by i.pl. injection of the JNK inhibitor, SP600125. In cultures of peripheral sensory neurons, norBNI activated JNK for at least 30 minutes. Furthermore, norBNI blocked KOR-mediated inhibition of adenylyl cyclase activity measured 24 hours later in a JNK-dependent manner, but did not block activation of extracellular signal-regulated kinase (ERK). The long-term inhibitory effect of norBNI on KOR function in vivo and ex vivo was blocked by inhibitors of mRNA translation, cycloheximide and rapamycin. These data suggest that in peripheral sensory neurons norBNI is a KOR-biased ligand for activation of JNK signaling, resulting in long-term blockade of some (antinociception, inhibition of adenylyl cyclase activity), but not all (ERK), KOR signaling. Importantly, norBNI elicits de novo protein synthesis in sensory neuron terminals that produces selective long-term regulation of KOR.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27605628      PMCID: PMC5074480          DOI: 10.1124/jpet.116.235184

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  65 in total

1.  Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.

Authors:  Laura C Sullivan; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2015-01-30       Impact factor: 4.030

2.  Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

Authors:  A S Portoghese; A W Lipkowski; A E Takemori
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

Review 3.  Axonal protein synthesis: a potential target for pain relief?

Authors:  Ilona Obara; Sandrine M Géranton; Stephen P Hunt
Journal:  Curr Opin Pharmacol       Date:  2011-10-25       Impact factor: 5.547

4.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

5.  Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation.

Authors:  Chan Y Shin; Mitchell Kundel; David G Wells
Journal:  J Neurosci       Date:  2004-10-20       Impact factor: 6.167

6.  Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats.

Authors:  Yan Zhou; Francesco Leri; Stephanie L Grella; Jane V Aldrich; Mary Jeanne Kreek
Journal:  Synapse       Date:  2013-02-26       Impact factor: 2.562

7.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

8.  Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Authors:  Lars Arendt-Nielsen; Anne E Olesen; Camilla Staahl; Frédérique Menzaghi; Sherron Kell; Gilbert Y Wong; Asbjørn M Drewes
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

9.  Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation?

Authors:  J L Joris; R Dubner; K M Hargreaves
Journal:  Anesth Analg       Date:  1987-12       Impact factor: 5.108

10.  Rapid modulation of micro-opioid receptor signaling in primary sensory neurons.

Authors:  Kelly A Berg; Amol M Patwardhan; Teresa A Sanchez; Yamille M Silva; Kenneth M Hargreaves; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

View more
  3 in total

Review 1.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

2.  Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Authors:  Kelsey M Nation; Milena De Felice; Pablo I Hernandez; David W Dodick; Volker Neugebauer; Edita Navratilova; Frank Porreca
Journal:  Pain       Date:  2018-05       Impact factor: 7.926

Review 3.  Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.

Authors:  Kelly A Berg; William P Clarke
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.